DrugCite
Search

NUTROPIN AQ

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Nutropin Aq Adverse Events Reported to the FDA Over Time

How are Nutropin Aq adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nutropin Aq, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nutropin Aq is flagged as the suspect drug causing the adverse event.

Most Common Nutropin Aq Adverse Events Reported to the FDA

What are the most common Nutropin Aq adverse events reported to the FDA?

Convulsion
55 (2.91%)
Scoliosis
37 (1.96%)
Headache
35 (1.85%)
Pneumonia
28 (1.48%)
Vomiting
24 (1.27%)
Overdose
23 (1.22%)
Fall
20 (1.06%)
Condition Aggravated
19 (1%)
Intracranial Pressure Increased
19 (1%)
Oedema Peripheral
19 (1%)
Pyrexia
19 (1%)
Show More Show More
Neoplasm Recurrence
18 (.95%)
Craniopharyngioma
16 (.85%)
Diabetes Mellitus
16 (.85%)
Urticaria
16 (.85%)
Accidental Overdose
14 (.74%)
Chest Pain
14 (.74%)
Lethargy
14 (.74%)
Blood Glucose Increased
13 (.69%)
Diarrhoea
13 (.69%)
Hypertension
13 (.69%)
Weight Increased
13 (.69%)
Arthralgia
12 (.63%)
Brain Oedema
12 (.63%)
Fatigue
12 (.63%)
Medication Error
12 (.63%)
Device Failure
11 (.58%)
Benign Intracranial Hypertension
10 (.53%)
Brain Neoplasm
10 (.53%)
Somnolence
10 (.53%)
Cerebrovascular Accident
9 (.48%)
Cough
9 (.48%)
Hypoaesthesia
9 (.48%)
Hypoglycaemia
9 (.48%)
Injection Site Irritation
9 (.48%)
Medical Device Complication
9 (.48%)
Nausea
9 (.48%)
Dehydration
8 (.42%)
Device Malfunction
8 (.42%)
Hepatic Cirrhosis
8 (.42%)
Incorrect Dose Administered
8 (.42%)
Joint Swelling
8 (.42%)
Pain
8 (.42%)
Speech Disorder
8 (.42%)
Weight Decreased
8 (.42%)
Abdominal Pain
7 (.37%)
Dizziness
7 (.37%)
Walking Disability
7 (.37%)
Asthenia
6 (.32%)
Atelectasis
6 (.32%)
Blood Creatinine Increased
6 (.32%)
Clavicle Fracture
6 (.32%)
Dyspnoea
6 (.32%)
Epiphysiolysis
6 (.32%)
Feeling Abnormal
6 (.32%)
Haematuria
6 (.32%)
Hospitalisation
6 (.32%)
Hypotension
6 (.32%)
Hypothyroidism
6 (.32%)
Medulloblastoma
6 (.32%)
Recurrent Cancer
6 (.32%)
Respiratory Arrest
6 (.32%)
Treatment Noncompliance
6 (.32%)
Viral Infection
6 (.32%)
Acromegaly
5 (.26%)
Acute Lymphocytic Leukaemia
5 (.26%)
Adrenal Insufficiency
5 (.26%)
Amnesia
5 (.26%)
Arthritis
5 (.26%)
Back Pain
5 (.26%)
Bone Sarcoma
5 (.26%)
Cardiovascular Disorder
5 (.26%)
Completed Suicide
5 (.26%)
Crying
5 (.26%)
Cystic Fibrosis
5 (.26%)
Death
5 (.26%)
Gait Disturbance
5 (.26%)
Guillain-barre Syndrome
5 (.26%)
Haemoglobin Decreased
5 (.26%)
Heart Rate Increased
5 (.26%)
Joint Dislocation
5 (.26%)
Lymphadenitis
5 (.26%)
Muscle Twitching
5 (.26%)
Myocardial Infarction
5 (.26%)
Obsessive-compulsive Disorder
5 (.26%)
Osteochondroma
5 (.26%)
Osteochondrosis
5 (.26%)
Ovarian Cyst
5 (.26%)
Palpitations
5 (.26%)
Pancreatitis
5 (.26%)
Papilloedema
5 (.26%)
Pituitary Tumour Benign
5 (.26%)
Respiratory Distress
5 (.26%)
Staphylococcal Infection
5 (.26%)
Swelling
5 (.26%)
Upper Limb Fracture
5 (.26%)
Visual Acuity Reduced
5 (.26%)
Anorexia
4 (.21%)
Arteriovenous Malformation
4 (.21%)
B Precursor Type Acute Leukaemia
4 (.21%)
Balance Disorder
4 (.21%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Nutropin Aq, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nutropin Aq is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nutropin Aq

What are the most common Nutropin Aq adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nutropin Aq, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nutropin Aq is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Nutropin Aq According to Those Reporting Adverse Events

Why are people taking Nutropin Aq, according to those reporting adverse events to the FDA?

Growth Hormone Deficiency
332
Body Height Below Normal
74
Drug Use For Unknown Indication
62
Hypopituitarism
60
Growth Retardation
47
Product Used For Unknown Indication
44
Show More Show More
Renal Failure Chronic
31
Turners Syndrome
28
Prader-willi Syndrome
16
Unevaluable Event
14
Pituitary Tumour Benign
13
Empty Sella Syndrome
8
Hypothalamo-pituitary Disorder
8
Radiotherapy
7
Renal Failure
7
Small For Dates Baby
6
Craniopharyngioma
6
Central Nervous System Neoplasm
4
Neoplasm Malignant
4
Dwarfism
4
Noonan Syndrome
4
Lung Disorder
3
Renal Disorder
3
Chromosome Abnormality
3
Failure To Thrive
3
Congenital Cystic Kidney Disease
3
Blood Growth Hormone
3
Cystic Fibrosis
3
Optic Nerve Hypoplasia
3
Blood Growth Hormone Decreased
2
Cardiovascular Disorder
2
Osteogenesis Imperfecta
2
Pituitary Tumour
2
Hepatic Cirrhosis
2
Surgery
2
Optic Tract Glioma
2
Nervous System Disorder
2
Acute Lymphocytic Leukaemia
2
Renal Dysplasia
2
Acute Leukaemia
1
Hypoglycaemia
1
Developmental Delay
1
Motor Neurone Disease
1
Brain Neoplasm
1
Hypothalamo-pituitary Disorders
1
Ill-defined Disorder
1
Hepatic Steatosis
1
Precocious Puberty
1
Osteoporosis
1
Gene Mutation
1
Type Iia Hyperlipidaemia
1

Drug Labels

LabelLabelerEffective
Nutropin Aq Pen 20Genentech, Inc.17-JAN-08
Nutropin AqGenentech, Inc.17-JAN-08
Nutropin Aq Pen 10Genentech, Inc.17-JAN-08
Nutropin Aq Nuspin 5Genentech, Inc.17-JAN-08
Nutropin Aq Nuspin 10Genentech, Inc.17-JAN-08
Nutropin Aq Nuspin 20Genentech, Inc.17-JAN-08

Nutropin Aq Case Reports

What Nutropin Aq safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Nutropin Aq. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Nutropin Aq.